Crypto derivatives should be banks’ ‘gateway drug’ to spot: B2C2

Improved spot market liquidity means cash-settled derivatives shouldn’t be the end goal, says co-founder


Cash-settled crypto derivatives should not be the end goal for banks, according to one of the founders of crypto market-maker B2C2; rather they should be a “gateway drug” to trade the physical product, for which liquidity conditions have improved significantly.

Banks including Goldman Sachs and Nomura have been among the traditional finance world’s first movers in trading bitcoin futures and non-deliverable forwards, while several other futures commission merchants (FCMs) have offered clearing

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options


Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here